Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $42.00 at HC Wainwright

Bicara Therapeutics (NASDAQ:BCAX) had its price target lifted by HC Wainwright from $40.00 to $42.00 in a research note published on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Citigroup began coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Wedbush reissued an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Finally, Citizens Jmp initiated coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target for the company. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $28.00.

Bicara Therapeutics Trading Up 4.5%

BCAX opened at $19.89 on Tuesday. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -7.86 and a beta of -0.78. Bicara Therapeutics has a 1-year low of $7.80 and a 1-year high of $20.25. The company’s fifty day moving average price is $17.21 and its two-hundred day moving average price is $16.67.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.04. As a group, equities analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Raben sold 16,300 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total value of $301,876.00. Following the sale, the insider directly owned 55,286 shares in the company, valued at approximately $1,023,896.72. The trade was a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ivan Hyep sold 13,555 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $18.22, for a total transaction of $246,972.10. Following the sale, the chief financial officer owned 145,355 shares in the company, valued at $2,648,368.10. This represents a 8.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 137,969 shares of company stock valued at $2,586,198 over the last three months.

Institutional Trading of Bicara Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $45,000. Legal & General Group Plc lifted its position in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after acquiring an additional 1,474 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares in the last quarter.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Phase‑3 advancement and clinical catalysts: Bicara selected a 1,500 mg weekly dose of ficerafusp alfa and has initiated the pivotal FORTIFI‑HN01 trial with interim Phase‑3 readout expected mid‑2027; long‑term Phase‑1b follow‑up is slated for ASCO 2026 — these program milestones underpin upside potential. Article Title
• Positive Sentiment: Corporate update & financials: Q4/FY‑2025 release highlighted a strong cash position, selection of the Phase‑3 dose, and a less‑frequent dosing regimen in development — gives runway to reach clinical milestones. Article Title
• Positive Sentiment: Strong buy-side analyst support from some firms: HC Wainwright reiterated a Buy and boosted its PT to $42; Citizens Jmp and Wedbush reaffirmed market/outperform views with $31 and $30 targets — these bulls can attract momentum buyers. Article Title
• Neutral Sentiment: Modest Q4 beat: Bicara reported EPS of ($0.68) vs. consensus ($0.72) — a small beat but still operating at losses as expected for a clinical‑stage biotech. Press Release
• Neutral Sentiment: Mixed mid‑range analyst moves: Goldman Sachs and Wells Fargo raised price targets to $16 but kept Neutral/Equal‑Weight ratings (their PTs sit below the current trading level), which tempers upside for cautious investors. Article Title
• Negative Sentiment: Insider sale: CEO Claire Mazumdar sold ~8,234 shares (~$154k) in early March, trimming her direct holdings — a small insider sale but some investors view insider selling as a cautionary signal. Article Title

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.